Christopher P Wild

Summary

Affiliation: International Agency for Research on Cancer
Country: France

Publications

  1. pmc Tobacco smoking and the British doctors' cohort
    P Boyle
    Br J Cancer 92:419-20. 2005
  2. doi request reprint Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk
    Christopher P Wild
    International Agency for Research on Cancer, 150 cours Albert Thomas, Lyon, France
    Environ Mol Mutagen 54:480-99. 2013
  3. pmc The role of cancer research in noncommunicable disease control
    Christopher Paul Wild
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Natl Cancer Inst 104:1051-8. 2012
  4. ncbi request reprint The globalisation of cancer
    Peter Boyle
    International Agency for Research on Cancer, 69372 Lyon Cedex, France
    Lancet 368:629-30. 2006
  5. ncbi request reprint Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia
    P Boyle
    Department of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BJU Int 93:751-6. 2004
  6. ncbi request reprint 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery
    P Boyle
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Eur Urol 45:620-6; discussion 626-7. 2004
  7. ncbi request reprint Tobacco: deadly in any form or disguise
    Peter Boyle
    International Agency for Research on Cancer, 69372 Lyon, France
    Lancet 367:1710-2. 2006
  8. pmc Mycotoxins and human disease: a largely ignored global health issue
    Christopher P Wild
    International Agency for Research on Cancer, 69372 Lyon Cedex 08, France
    Carcinogenesis 31:71-82. 2010
  9. ncbi request reprint Cancer incidence and mortality in Europe, 2004
    P Boyle
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Ann Oncol 16:481-8. 2005
  10. pmc Future research perspectives on environment and health: the requirement for a more expansive concept of translational cancer research
    Christopher P Wild
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69000 Lyon Cedex 08, France
    Environ Health 10:S15. 2011

Detail Information

Publications74

  1. pmc Tobacco smoking and the British doctors' cohort
    P Boyle
    Br J Cancer 92:419-20. 2005
  2. doi request reprint Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk
    Christopher P Wild
    International Agency for Research on Cancer, 150 cours Albert Thomas, Lyon, France
    Environ Mol Mutagen 54:480-99. 2013
    ..Such an interdisciplinary approach is vital if the full benefits of advances in laboratory sciences and investments in large-scale prospective cohort studies are to be realized in relation to cancer prevention...
  3. pmc The role of cancer research in noncommunicable disease control
    Christopher Paul Wild
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Natl Cancer Inst 104:1051-8. 2012
    ..Finally, the need for global cooperation in developing a research agenda for low- and middle-income countries is highlighted...
  4. ncbi request reprint The globalisation of cancer
    Peter Boyle
    International Agency for Research on Cancer, 69372 Lyon Cedex, France
    Lancet 368:629-30. 2006
  5. ncbi request reprint Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia
    P Boyle
    Department of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BJU Int 93:751-6. 2004
    ....
  6. ncbi request reprint 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery
    P Boyle
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Eur Urol 45:620-6; discussion 626-7. 2004
    ..This analysis examines the relative effectiveness of current medical therapies for BPH in preventing AUR, AUR-related catheterisation and surgery in real-life clinical practice...
  7. ncbi request reprint Tobacco: deadly in any form or disguise
    Peter Boyle
    International Agency for Research on Cancer, 69372 Lyon, France
    Lancet 367:1710-2. 2006
  8. pmc Mycotoxins and human disease: a largely ignored global health issue
    Christopher P Wild
    International Agency for Research on Cancer, 69372 Lyon Cedex 08, France
    Carcinogenesis 31:71-82. 2010
    ....
  9. ncbi request reprint Cancer incidence and mortality in Europe, 2004
    P Boyle
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Ann Oncol 16:481-8. 2005
    ..Those data that are available generally refer to the mid-1990s and are of limited use for cancer control planning. We present estimates of the cancer burden in Europe in 2004, including data for the (25 Member States) European Union...
  10. pmc Future research perspectives on environment and health: the requirement for a more expansive concept of translational cancer research
    Christopher P Wild
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69000 Lyon Cedex 08, France
    Environ Health 10:S15. 2011
    ....
  11. ncbi request reprint Breast cancer control: signs of progress, but more work required
    Peter Boyle
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex08, France
    Breast 14:429-38. 2005
    ..The declines seen in mortality represent a considerable success, but there is no room for complacency until research can impact positively on reducing incidence...
  12. ncbi request reprint Mortality and survival in breast and colorectal cancer
    Peter Boyle
    International Agency for Research on Cancer, Lyon, France
    Nat Clin Pract Oncol 2:424-5. 2005
  13. pmc Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation
    Zdenko Herceg
    International Agency for Research on Cancer IARC, 150 cours Albert Thomas, F 69008 Lyon, France
    Carcinogenesis 34:1955-67. 2013
    ....
  14. doi request reprint Proteomic analysis of the effects of the immunomodulatory mycotoxin deoxynivalenol
    André Nogueira da Costa
    Division of Epidemiology, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK
    Proteomics 11:1903-14. 2011
    ..These findings provide insights as to how low-dose exposure to DON may affect human immune function and may provide mechanism-based biomarkers for DON exposure...
  15. ncbi request reprint Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident
    Elisabeth Cardis
    International Agency for Research on Cancer, Lyon, France
    Int J Cancer 119:1224-35. 2006
    ....
  16. ncbi request reprint Curbing tobacco's toll starts with the professionals: World No Tobacco Day
    Peter Boyle
    International Agency for Research on Cancer, Lyon, France
    Lancet 365:1990-2. 2005
  17. ncbi request reprint A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia
    Peter Boyle
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    BJU Int 94:83-8. 2004
    ..To investigate the short- and long-term effectiveness of transurethral needle ablation (TUNA) of the prostate for clinical benign prostatic hyperplasia (BPH), using a meta-analysis of all clinical studies involving TUNA...
  18. ncbi request reprint 'Environment' in cancer causation and etiological fraction: limitations and ambiguities
    Paolo Boffetta
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69008 Lyon, France
    Carcinogenesis 28:913-5. 2007
  19. pmc Preventable exposures associated with human cancers
    Vincent James Cogliano
    Section of IARC Monographs, International Agency for Research on Cancer, World Health Organization, Lyon, France
    J Natl Cancer Inst 103:1827-39. 2011
    ..Nevertheless, some common human cancers still have few (or no) identified causal agents...
  20. doi request reprint An estimate of cancers attributable to occupational exposures in France
    Paolo Boffetta
    International Prevention Research Institute, Lyon, France
    J Occup Environ Med 52:399-406. 2010
    ..To perform a quantitative estimate of the proportion of cancers attributable to occupational exposures in France in 2000...
  21. ncbi request reprint Epidemiology of colorectal cancer
    Peter Boyle
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Br Med Bull 64:1-25. 2002
    ..Achieving colorectal cancer control is the immediate challenge...
  22. ncbi request reprint Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy
    Umberto Veronesi
    Scientific Directorate, European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 99:727-37. 2007
    ..Here we present an extended follow-up of the Italian trial...
  23. ncbi request reprint Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women
    Umberto Veronesi
    European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 95:160-5. 2003
    ..Such a strategy would greatly reduce the numbers of women who would need to take tamoxifen to obtain the same absolute reduction in breast cancer. These findings are exploratory and need to be confirmed in other randomized trials...
  24. ncbi request reprint Declining mortality from bladder cancer in Europe
    Jacques Ferlay
    International Agency for Research on Cancer, Lyon Cedex, France
    BJU Int 101:11-9. 2008
    ....
  25. doi request reprint Meeting the global demands of epidemiologic transition - the indispensable role of cancer prevention
    Silvia Franceschi
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Mol Oncol 7:1-13. 2013
    ..It is only by complementing efforts to improve treatment with those aimed at prevention that the impending epidemic of this disease can be addressed...
  26. ncbi request reprint Upper urinary tract urothelial cancers: where it is A:T
    Magali Olivier
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, France
    Nat Rev Cancer 12:503-4. 2012
    ..Despite a ban on the use of plants of the Aristolochia genus in herbal medicine, as they contain known carcinogens, urothelial carcinoma attributable to the use of this plant seems to be more common than previously thought...
  27. ncbi request reprint The future of the nicotine-addiction market
    Nigel Gray
    Division of Epidemiology and Biostatistics, European Institute of Oncology, 20141, Milan, Italy
    Lancet 362:845-6. 2003
  28. ncbi request reprint Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial
    Andrea Decensi
    Divisions of Chemoprevention, European Institute of Oncology, Milan, Italy
    Circulation 111:650-6. 2005
    ..Atherosclerosis may induce VTE, or the 2 conditions may share common risk factors. We assessed the effect of tamoxifen on VTE in a breast cancer prevention trial and studied its association with risk factors for VTE...
  29. ncbi request reprint Tobacco smoking and cancer: a meta-analysis
    Sara Gandini
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Int J Cancer 122:155-64. 2008
    ..The analysis of heterogeneity showed that study type, gender and adjustment for confounding factors significantly influence the RRs estimates and the reliability of the studies...
  30. ncbi request reprint Mammographic breast cancer screening: after the dust has settled
    Peter Boyle
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Breast 12:351-6. 2003
  31. ncbi request reprint Breast cancer
    Umberto Veronesi
    European Institute of Oncology, Milan, Italy
    Lancet 365:1727-41. 2005
    ..Assessment of potential molecular targets is now important in primary diagnosis. Tyrosine-kinase inhibitors and other drugs with anti-angiogenesis properties are currently undergoing preclinical investigations...
  32. ncbi request reprint Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi
    Sara Gandini
    Department of Epidemiology and Biostatistics, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
    Eur J Cancer 41:28-44. 2005
    ..Case-control studies, in particular when the hospital was the source for cases or controls, appeared to present much lower and more precise estimates than cohort studies...
  33. ncbi request reprint Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors
    Sara Gandini
    Department of Epidemiology and Biostatistics, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
    Eur J Cancer 41:2040-59. 2005
    ..Sensitivity analyses investigated reliability of results and publication bias. Latitude and adjustment for phenotype were two study characteristics that significantly influenced the estimates...
  34. doi request reprint Artificial ultraviolet sources and skin cancers: rationale for restricting access to sunbed use before 18 years of age
    Philippe Autier
    International Agency for Research, Lyon, France
    Nat Clin Pract Oncol 5:178-9. 2008
  35. doi request reprint Past medical history and pancreatic cancer risk: Results from a multicenter case-control study
    Patrick Maisonneuve
    European Institute of Oncology, Milan, Italy
    Ann Epidemiol 20:92-8. 2010
    ..To investigate risk factors that may be linked to pancreatic cancer...
  36. ncbi request reprint Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure
    Sara Gandini
    Department of Epidemiology and Biostatistics, European Institute of Oncology, IRCCS Via Ripamonti 435, 20141 Milan, Italy
    Eur J Cancer 41:45-60. 2005
    ....
  37. ncbi request reprint ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer
    Gianluca Severi
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 95:818-24. 2003
    ..In five of the seven total studies, subject selection was influenced by prostate-specific antigen (PSA) levels. We examined the association and possible effect of subject selection in a larger study and a meta-analysis...
  38. ncbi request reprint Testicular cancer: the challenge for cancer control
    Peter Boyle
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Lancet Oncol 5:56-61. 2004
    ..Testicular cancer control would be the finest illustration of this process and, simultaneously, would be a model for implementation as new, successful therapeutic modalities for other cancers are developed...
  39. ncbi request reprint 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia
    Vanessa M Hayes
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, Australia
    Int J Cancer 120:776-80. 2007
    ..These findings raise important questions with respect to previous assumptions concerning hormonal influences on prostate cancer risk in ageing males...
  40. doi request reprint The challenge of cancer control in Africa
    Rebecca J Lingwood
    Department for Continuing Education, University of Oxford, Littlegate House, 16 17 St Ebbes street, Oxford, OX1 1PT, UK
    Nat Rev Cancer 8:398-403. 2008
    ..Many of these cancers are preventable, or treatable when detected early enough. Establishing effective, affordable and workable cancer control plans in African countries is one step in the right direction toward limiting this epidemic...
  41. ncbi request reprint The role of the dental team in preventing and diagnosing cancer: 1. cancer in general
    Crispian Scully
    Eastman Dental Institute for Oral Health Care Sciences, University College London, 256 Gray s Inn Road, London WC1X 8LD
    Dent Update 32:204-6, 208-10, 212. 2005
    ..The signs and symptoms of cancer often resemble less serious conditions and prompt referral to an appropriate specialist usually allows for the best management...
  42. ncbi request reprint Screening for prostate cancer: updated experience from the Tyrol study
    Wolfgang Horninger
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Can J Urol 12:7-13; discussion 92-3. 2005
    ....
  43. ncbi request reprint Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis
    Frans Debruyne
    Department of Urology, Academic Hospital Nijmegen, Geert Grooteplein Zuid 16, 426 Afdeling Urologie, 6500 HB Nijmegen, The Netherlands
    Eur Urol 45:773-9; disucssion 779-80. 2004
    ..To compare the efficacy of the lipido-sterolic extract of Serenoa repens, Permixon, to that of the alpha-blocker, tamsulosin, in the treatment of severe low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH)...
  44. ncbi request reprint Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results
    Ugo Pastorino
    Division of Thoracic Surgery, Istituto Nazionale Tumori, Milan, Italy
    Lancet 362:593-7. 2003
    ..We investigated the efficacy of repeated yearly spiral CT and selective use of positron emission tomography (PET) in a large cohort of high-risk volunteers...
  45. ncbi request reprint Recent trends in mortality from benign prostatic hyperplasia
    Fabio Levi
    Cancer Epidemiology Unit and Cancer Registries of Vaud and Neuchâtel, Institut Universitaire de Medecine Sociale et Preventive, CHUV Falaises 1, 1011 Lausanne, Switzerland
    Prostate 56:207-11. 2003
    ..We have considered trends in mortality from benign prostatic hyperplasia (BPH) over the last decades in Europe and, for comparative purposes, the USA and Japan...
  46. ncbi request reprint Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial
    Roger S Kirby
    St George s Hospital, London, United Kingdom
    Urology 61:119-26. 2003
    ..To evaluate the efficacy and tolerability of the selective alpha(1)-adrenergic antagonist doxazosin and the 5-alpha-reductase inhibitor finasteride, alone and in combination, for the symptomatic treatment of benign prostatic hyperplasia...
  47. ncbi request reprint Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand
    John H Stewart
    Department of Medical and Surgical Sciences, University of Otago, Dunedin, New Zealand
    J Am Soc Nephrol 14:197-207. 2003
    ....
  48. ncbi request reprint An estimate of prostate cancer prevalence in Italy
    Carlo La Vecchia
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Tumori 88:367-9. 2002
    ..The number of clinically detected cases, including cases with advanced disease, is less subject to uncertainty, with reasonable estimates ranging from 45,000 to 60,000...
  49. ncbi request reprint Cigarette smoking, glutathione-s-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States)
    Tongzhang Zheng
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510, USA
    Cancer Causes Control 13:637-45. 2002
    ..We sought to determine if there is a gene-environment interaction between GSTM I (GSTM1A and GSTM1B), and GSTT1 genotypes and cigarette smoking in the risk of breast cancer...
  50. ncbi request reprint [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]
    Frans Debruyne
    Academic Hospital Nijmegen, Nijmegen Sint Radboud, Pays Bas
    Prog Urol 12:384-92; discussion 394-4. 2002
    ..The aim of this study was to assess the equivalent efficacy of Permixon and tamsulosin...
  51. ncbi request reprint Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study
    Frans Debruyne
    Academic Hospital Nijmegen Sint Radboud, Nijmegen, The Netherlands
    Eur Urol 41:497-506; discussion 506-7. 2002
    ..The aim of this study was to assess the equivalent efficacy of Permixon and tamsulosin...
  52. ncbi request reprint Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)
    Raymond Rosen
    Department of Psychiatry, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA
    Eur Urol 44:637-49. 2003
    ..This study was conducted to investigate the relationship between LUTS and sexual problems in aging men...
  53. ncbi request reprint Leveling of prostate cancer mortality in Western Europe
    Fabio Levi
    Cancer Epidemiology Unit and Cancer Registries of Vaud and Neuchâtel, Institut Universitaire de Medecine Sociale et Preventive, Lausanne, Switzerland
    Prostate 60:46-52. 2004
    ..Trends in 24 European countries, the European Union (EU), six selected Central and Eastern European countries, and the Russian Federation have been updated to 1999...
  54. ncbi request reprint [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]
    Frans Debruyne
    Hôpital Universitaire Saint Radboud, Nijmegen, Pays Bas
    Prog Urol 14:326-31. 2004
    ..To compare the efficacy of the lipido-sterolic extract of Serenoa repens, Permixon, to that of the a-blocker, tamsulosin, in the treatment of severe low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH)...
  55. ncbi request reprint Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women
    Yawei Zhang
    Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT, USA
    Am J Epidemiol 160:766-73. 2004
    ..These findings support a reduced risk of non-Hodgkin's lymphoma associated with multiple pregnancies and an increased risk of non-Hodgkin's lymphoma associated with later age at menarche...
  56. ncbi request reprint Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960
    Fabio Levi
    Unité d Epidémiologie du Cancer and Registres Vaudois et Neuchâtelois des Tumeurs, Institut Universitaire de Medecine Sociale et Preventive, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Int J Cancer 110:155-69. 2004
    ..Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html..
  57. ncbi request reprint A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma
    Yawei Zhang
    Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT 06520 8034, USA
    J Natl Cancer Inst 97:1616-8. 2005
    ..2, 95% CI = 2.0 to 13.3). Our results support the hypothesis that a genetic variant that could alter mRNA transcripts of BCL6 may contribute to the etiology of NHL and suggest that this variant warrants further investigation...
  58. ncbi request reprint Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 60:434-41. 2002
    ..To study the efficacy and safety of dutasteride, a dual inhibitor of the 5-alpha-reductase isoenzymes types I and II...
  59. pmc Publishing tobacco tar measurements on packets
    Nigel Gray
    BMJ 329:813-4. 2004
  60. ncbi request reprint Beyond classical meta-analysis: can inadequately reported studies be included?
    Chris Robertson
    Department of Statistics and Modelling Science, University of Strathclyde, 26 Richmond Street, Glasgow, Scotland G1 1XH, UK
    Drug Discov Today 9:924-31. 2004
    ..Although multiple imputation techniques enable a larger number of studies to be included, which will typically increase the precision of the estimated effect, a careful sensitivity analysis is also required...
  61. ncbi request reprint Relation of childhood brain tumors to exposure of parents and children to tobacco smoke: the SEARCH international case-control study. Surveillance of Environmental Aspects Related to Cancer in Humans
    Graziella Filippini
    Neuroepidemiology Research Unit, Istituto Nazionale Neurologico C Besta, Milan, Italy
    Int J Cancer 100:206-13. 2002
    ..These results did not change considering the child's age at diagnosis, the histologic type of tumor or center...
  62. ncbi request reprint Serum polychlorinated biphenyls, cytochrome P-450 1A1 polymorphisms, and risk of breast cancer in Connecticut women
    Yawei Zhang
    Department of Epidemiology and Public Health, School of Medicine, Yale University, New Haven, CT 06510, USA
    Am J Epidemiol 160:1177-83. 2004
    ..In summary, the CYP1A1 m2 genetic polymorphism was associated with increased risk of female breast cancer and may modify the relation between PCB exposure and breast cancer risk...
  63. ncbi request reprint Androgenetic alopecia and prostate cancer: findings from an Australian case-control study
    Graham G Giles
    Cancer Epidemiology Centre, Anti Cancer Council of Victoria, Melbourne, VIC 3053 Australia
    Cancer Epidemiol Biomarkers Prev 11:549-53. 2002
    ..91 (1.59-5.32) for vertex baldness; and 1.95 (1.10-3.45) for frontal and vertex baldness. This association between the pattern of AA and prostate cancer points to shared androgen pathways that are worthy of additional investigation...
  64. ncbi request reprint Testicular cancer mortality in Eastern Europe
    Fabio Levi
    Int J Cancer 105:574. 2003
  65. ncbi request reprint Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer
    Laura Baglietto
    Cancer Epidemiology Centre, The Cancer Council of Victoria, 100 Rathdowne Street, Carlton, Melbourne, Victoria 3053, Australia
    J Clin Epidemiol 59:114-24. 2006
    ....
  66. ncbi request reprint Cancer of the skin: a forgotten problem in Europe
    Peter Boyle
    Ann Oncol 15:5-6. 2004
  67. ncbi request reprint Screening for prostate cancer: updated experience from the Tyrol study
    Wolfgang Horninger
    Department of Urology, University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Curr Urol Rep 5:220-5. 2004
    ..It is our opinion that most of this decline is likely a result of aggressive downstaging and successful treatment and that any contribution from detecting and treating early cancers will become apparent in the years to come...
  68. ncbi request reprint Tobacco control, screening, and collaboration are priorities for IARC, incoming director says. Interview with Peter Boyle
    Peter Boyle
    J Natl Cancer Inst 95:1653-5. 2003
  69. ncbi request reprint Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States)
    Lindsay McOmber Morton
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Causes Control 14:687-94. 2003
    ..Data from a population-based case-control study among women in Connecticut were analyzed to determine the potential impact of alcohol consumption on risk of NHL...
  70. ncbi request reprint Circulating steroid hormones and the risk of prostate cancer
    Gianluca Severi
    Cancer Epidemiology Centre, The Cancer Council Victoria, University of Melbourne, Melbourne, Australia
    Cancer Epidemiol Biomarkers Prev 15:86-91. 2006
    ..06, 0.2, and 0.1, respectively). High levels of testosterone and adrenal androgens are thus associated with reduced risk of aggressive prostate cancer but not with nonaggressive disease...
  71. ncbi request reprint Is FOB screening really the answer for lowering mortality in colorectal cancer?
    Philippe Autier
    Centre for Research in Epidemiology CRESIS, Luxembourg Health Institute, Luxembourg, Luxembourg
    Recent Results Cancer Res 163:254-63; discussion 264-6. 2003
    ..Therefore, recommending general population screening with biennial FOBT is still an open question...
  72. doi request reprint The changing pattern of kidney cancer incidence and mortality in Europe
    Fabio Levi
    Unité d épidemiologie du cancer et Registres des tumeurs de Vaud et Neuchâtel, Institut de Medecine Sociale et Preventive, Centre Hospitalier Universitaire Vaudois et Universite de Lausanne, Lausanne, Switzerland
    BJU Int 101:949-58. 2008
    ....
  73. ncbi request reprint A new face at the IARC
    Emma Wilkinson
    Lancet Oncol 4:386. 2003
  74. ncbi request reprint Ultraviolet radiation exposure and risk of non-Hodgkin's lymphoma
    Yawei Zhang
    Yale University School of Epidemiology and Public Health, New Haven, CT 06520 8034, USA
    Am J Epidemiol 165:1255-64. 2007
    ..0051). The risk appears to vary by non-Hodgkin's lymphoma subtypes. Further investigations of the role of ultraviolet radiation on the risk of non-Hodgkin's lymphoma are warranted...